CEACAM5 and adenocarcinoma: There is no difference in CEA or CYFRA21-1 levels between EGFR-positive and wild-type adenocarcinoma patients.CYFRA21-1 serves as a predictive and prognostic marker in resectable adenocarcinoma patients with EGFR mutations, particularly in the EGFR del19 or L858R groups.CEA is an independent predictive and prognostic factor only for EGFR wild-type adenocarcinoma and EGFR L858R adenocarcinoma patients.